Linda Lebon
General Counsel bei OSE IMMUNOTHERAPEUTICS
Aktive Positionen von Linda Lebon
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
OSE IMMUNOTHERAPEUTICS | General Counsel | 20.12.2021 | - |
Karriereverlauf von Linda Lebon
Ehemalige bekannte Positionen von Linda Lebon
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
BIOSENIC SA | General Counsel | 29.10.2018 | 01.09.2021 |
ARGENX SE | General Counsel | - | - |
iTeos Therapeutics SA
iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | General Counsel | - | - |
Ausbildung von Linda Lebon
École des Hautes Études Commerciales de Paris | Masters Business Admin |
Centre Hospitalier Universitaire de Liege | Graduate Degree |
Statistik
International
Belgien | 4 |
Frankreich | 3 |
Niederlande | 2 |
Operativ
General Counsel | 4 |
Masters Business Admin | 1 |
Graduate Degree | 1 |
Sektoral
Health Technology | 5 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
ARGENX SE | Health Technology |
OSE IMMUNOTHERAPEUTICS | Health Technology |
Private Unternehmen | 2 |
---|---|
iTeos Therapeutics SA
iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Health Technology |
Bone Therapeutics SA
Bone Therapeutics SA Pharmaceuticals: MajorHealth Technology Bone Therapeutics SA is a cell therapy company, which engages in the regenerative therapy addressing for unmet medical needs in the field of bone diseases and orthopedics. Its products include Allob and JTA-004. The company was founded by Jacques Reymann on June 16, 2006 and is headquartered in Gosselies, Belgium. | Health Technology |
- Börse
- Insiders
- Linda Lebon
- Erfahrung